x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAA-001252
| Product Information | |
|---|---|
| Product Name | Total NRF2 ELISA Kit |
| Species | Human |
| Description | Total NRF2 ELISA Kit is a sandwich enzyme-linked immunosorbent assay (ELISA) that detects endogenous levels of NRF2. To perform the assay, sample is incubated with a capture antibody conjugated with a proprietary tag and a second detection antibody linked to HRP, forming a sandwich with NRF2 in solution. This entire complex is immobilized to the plate via an anti-tag antibody. The wells are then washed to remove unbound material. TMB is then added. The magnitude of observed signal is proportional to the quantity of NRF2. |
| Component | ELISA Microwell Strip Plate, 96 Well; NRF2 Rabbit Capture mAb; NRF2 Rabbit HRP-linked mAb; ELISA Capture Antibody Diluent; ELISA HRP Antibody Diluent; TMB Substrate; STOP Solution; Sealing Tape; ELISA Wash Buffer (20X); ELISA Cell Extraction Buffer (5X); ELISA Cell Extraction Enhancer Solution (50X); ELISA KitIt5 Positive Control Type 2 |
| Target Information | |
|---|---|
| Target Name | NFE2L2 |
| UniProt No. | Q16236 |
| Gene ID | 4780 |
| Target Description | The nuclear factor-like 2. NRF2 activity in lung cancer cell lines directly correlates with cell proliferation rates, and inhibition of NRF2 expression by siRNA enhances anti-cancer drug-induced apoptosis. |
| Alternative Names | HEBP1; Nuclear factor - erythroid derived 2 - like 2 |
| Shipping & Storage | |
|---|---|
| Sipping | Shipping on dry ice. |
| Storage | Store at -20°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
